MHRA's Pharmaceutical Assessor, Marion Westwood, will share an opening address on Day One titled, "Supporting innovation in controlled release
and combination products.
20 September 2010 - Dutch-based drug delivery company OctoPlus NV (AMS: OCTO) said today that it has signed a feasibility agreement with an unnamedA US-based pharmaceutical company relating to the use of OctoPlus' controlled release
As part of this controlled release
program, Inhale has begun initial research funded by Pfizer Inc.
This book describes the theories, applications, and challenges for different oral controlled release
In addition to the array of pharma case studies, SMi is proud to announce that the MHRA and US FDA will be sharing their own unique perspectives at the 13th annual Controlled Release
conference, taking place on 18th - 19th April 2016 in London, highlighting scientific and regulatory challenges, along with how these have been overcome:
Analyzes and evaluates branded and proprietary controlled release
processes and technologies for oral therapeutic drugs
Furthermore, the MHRA and the US FDA will be sharing case studies at the 13th annual Controlled Release
The Company's strategy includes developing generic versions of controlled release
drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products.
There are many drugs currently on the market and many more in development that do not have ideal delivery characteristics and could potentially benefit from controlled release
This will enable Elite to enhance its focus on its abuse resistant and controlled release
opioid pain products, while maintaining a strong presence in the specialty generic drug industry through its interest in Novel," said Bernard Berk, Chairman and CEO of Elite Pharmaceuticals.
The particles manufactured using these technologies can be used in controlled release
, taste masking, respiratory, transdermal and injectable drug delivery applications.
ELI-216 is a combination of a narcotic agonist, oxycodone hydrochloride, and an antagonist, naltrexone hydrochloride, formulated as a controlled release
product to deter abuse of the drug.